- Home
- LX vs IRON Comparison
LX vs IRON Comparison
Compare LX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- IRON
- Stock Information
- Founded
- LX 2013
- IRON 2017
- Country
- LX China
- IRON United States
- Employees
- LX N/A
- IRON N/A
- Industry
- LX Finance: Consumer Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- IRON Health Care
- Exchange
- LX Nasdaq
- IRON Nasdaq
- Market Cap
- LX 1.3B
- IRON 1.4B
- IPO Year
- LX 2017
- IRON N/A
- Fundamental
- Price
- LX $6.91
- IRON $51.61
- Analyst Decision
- LX
- IRON Strong Buy
- Analyst Count
- LX 0
- IRON 10
- Target Price
- LX N/A
- IRON $93.40
- AVG Volume (30 Days)
- LX 2.1M
- IRON 372.4K
- Earning Date
- LX 05-21-2025
- IRON 08-07-2025
- Dividend Yield
- LX 2.67%
- IRON N/A
- EPS Growth
- LX 35.86
- IRON N/A
- EPS
- LX 1.07
- IRON N/A
- Revenue
- LX $1,938,367,396.00
- IRON N/A
- Revenue This Year
- LX $2.38
- IRON N/A
- Revenue Next Year
- LX $8.71
- IRON N/A
- P/E Ratio
- LX $6.62
- IRON N/A
- Revenue Growth
- LX 5.63
- IRON N/A
- 52 Week Low
- LX $1.57
- IRON $30.82
- 52 Week High
- LX $11.64
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- LX 38.40
- IRON 56.99
- Support Level
- LX $6.91
- IRON $48.87
- Resistance Level
- LX $7.84
- IRON $54.13
- Average True Range (ATR)
- LX 0.29
- IRON 2.31
- MACD
- LX -0.01
- IRON 0.07
- Stochastic Oscillator
- LX 12.29
- IRON 67.64
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.